Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ruxolitinib gel in adults with prurigo nodularis
ChiCTR2600117276Phase 3Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in prurigo nodularis (PN) (4 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Primary: Proportion of subjects with weekly average WI-NRS decrease ≥4 points at Week 16 vs baseline. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on ChiCTR2600117276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117276.